Eligible participants were patients (aged 18–75 years) with HER2-positive breast cancer who had received trastuzumab, taxane, and tyrosine kinase inhibitor (TKI) treatment, and also had at least one measurable active brain metastatic lesion (≥1 cm). The gene discussed is ERBB2; the disease is breast cancer.